Loading...
DOCUMENTS
20
NOTICES
33
MOTS CLES
Contraindication
IL12
Anti-TNF
Microbiote
Over 80s
Eradication
Survival
Rituximab plus chlorambucil
Colorectal cancer
Inhibitor
Disability
Crohn's disease
Monitoring
Tuberculosis
Gene expression
Venous thromboembolism
Microbiota
Clinical trial
DNA methylation
Rituximab
Colon cancer
Inclusion
Original Article Clinical
Effectiveness
PCR
Epigénétiques
Heart disease risk factors
Colorectal cancer Colibactin and lipids
Stricture
Anti-TNF agents
Tailored therapy
Ustekinumab
Cancer
IL23
Vedolizumab
Inflammatory Bowel Diseases
Patient-reported outcome
Bactéries
Therapeutics
MICROBIOTA
Dysbiose
RISK
Acceptability
MALT
Fecal microbiota
Endoscopic treatment
Ulcerative colitis
Intestinal crypts
Disease progression
Immune cells
COLON-CANCER
Résistance
Colonic epithelial primary cells
Safety
MORTALITY
Small molecules
Cell adhesion
Cost effectiveness
Drug
MARKER
Immunosuppressant
Primary sclerosing cholangitis
Disease Progression
Méthylation
Dysbiosis
Inflammatory bowel disease
Screening
Alkylating agents
IBD
Thérapie ciblée
Eligibility
Algorithm
DNA METHYLATION
Colectomy
Upper gastrointestinal tract
Resistance
18 FDG-PET/CT
Colon
Clinical guidelines
Consensus
Crohn’s disease
Gènes
Biologics
Epigenetics
Neoadjuvant chemotherapy
HIV
Kidney diseases
Parvimonas micra
Helicobacter pylori
Biomarker
Gene methylation
Inflammatory bowel diseases
Methylation
CARCINOGENESIS
Patients experience
Maintenance therapy
Genes
T1118 translocation
Bacteria
Surgery
Early detection of Colon Cancer using Molecular Markers and Microbiota , EA 7375 | |
---|---|
Institutions |
UPEC |
Adresse |
Université Paris-Est Créteil Groupe Hospitalier Henri Mondor Service de Gastroentérologie 51 Av Maréchal de Lattre de Tassigny 94010 Créteil cedex |
Courriel |
|
Site Internet |
|
Rattachement(s) |
|
Direction |
Aurélien AMIOT |
Adjoint |
Iradj SOBHANI |
Axe(s) de recherche
|
Le laboratoire axe ses recherches sur le rôle du microbiome intestinal ainsi que des changements épigénétiques dans l'intestin afin :
|